Physician profile
Julia Fiore
NPI 1215331384
$15,862.03
in general payments reported to CMS, 2019-2025
30 companies · $3,711 in 2025
The $3,711 reported for 2025 was more than what 97% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,813 · 2022: $3,567 · 2023: $2,295 · 2024: $4,476 · 2025: $3,711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,285.37 |
| Education | $196.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,981.41 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,554.75 | 2021-2025 | |
| Janssen Biotech, INC. | $1,546.97 | 2021-2025 | Tremfya, Simponi, Remicade |
| Ucb, INC. | $1,473.08 | 2021-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $980.90 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $955.91 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $751.59 | 2021-2025 | Dupixent |
| Amgen INC. | $749.45 | 2021-2025 | Otezla |
| Arcutis Biotherapeutics, INC. | $723.68 | 2023-2025 | Zoryve |
| Pfizer INC. | $688.95 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $662.67 | 2022-2025 | Ilumya, Winlevi, Absorica Ld |
| Incyte Corporation | $653.03 | 2021-2025 | Opzelura |
| Genzyme Corporation | $626.30 | 2021-2025 | |
| Leo Pharma INC. | $391.36 | 2021-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $326.14 | 2021-2025 | Nemluvio |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.74 | 2023-2025 | Spevigo, Cyltezo |
| Janssen Scientific Affairs, LLC | $113.65 | 2022 | |
| Dermavant Sciences, INC. | $111.19 | 2022-2024 | Vtama |
| Sanofi-Aventis U.S. LLC | $64.99 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $55.81 | 2022-2025 | Cabtreo, Jublia, Siliq |
| Verrica Pharmaceuticals INC. | $46.46 | 2024-2025 | Ycanth |
| Fresenius Kabi USA, LLC | $44.50 | 2023-2024 | Idacio |
| Tactile Systems Technology INC | $39.50 | 2023-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Organon LLC | $31.44 | 2025 | Vtama |
| Sandoz INC. | $29.80 | 2024 | Hyrimoz |
| Merz North America, INC. | $23.39 | 2022 | |
| Paratek Pharmaceuticals, INC. | $20.60 | 2024 | Nuzyra |
| Biofrontera INC. | $19.50 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $18.26 | 2025 | Valchlor |
| Botanix Sb INC | $18.01 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Fiore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.